Avedro
Company

Last deal

$25M

Amount

Series F

Stage

02.05.2018

Date

11

all rounds

$218.5M

Total amount

General

About Company
Avedro is a medical device and pharmaceutical company advancing the science and technology of corneal cross-linking.

Industry

Sector :

Subsector :

Keywords :

Also Known As

ThermalVision

founded date

01.01.2007

Number of employees

Company Type

For Profit

Last funding type

Series F

IPO status

Private

Description

The company has completed its Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery in the US, and has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking outside the US. Avedro is also developing the science of Thermo-biomechanics for therapeutic medical applications, with Keraflex being the first technology developed from the platform. Keraflex is a non-invasive, incision-less ophthalmic procedure for flattening the cornea without the removal of tissue, offering the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity. The company's Avedro Corneal Remodeling Platform is designed to strengthen, stabilize, and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions.
Contacts

Social url